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Abstract
The pan-protein kinase C (PKC) inhibitor sotrastaurin (AEB071) is a novel immunosuppressant currently in phase II trials for
immunosuppression after solid organ transplantation. Besides T-cell activation, PKC affects numerous cellular processes that
are potentially important for the replication of hepatitis B virus (HBV) and hepatitis C virus (HCV), major blood-borne
pathogens prevalent in solid organ transplant recipients. This study uses state of the art virological assays to assess the
direct, non-immune mediated effects of sotrastaurin on HBV and HCV. Most importantly, sotrastaurin had no pro-viral effect
on either HBV or HCV. In the presence of high concentrations of sotrastaurin, well above those used clinically and close to
levels where cytotoxic effects become detectable, there was a reduction of HCV and HBV replication. This reduction is very
likely due to cytotoxic and/or anti-proliferative effects rather than direct anti-viral activity of the drug. Replication cycle
stages other than genome replication such as viral cell entry and spread of HCV infection directly between adjacent cells
was clearly unaffected by sotrastaurin. These data support the evaluation of sotrastaurin in HBV and/or HCV infected
transplant recipients.
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Introduction
Worldwide about half a billion people are chronically infected
with the hepatitis B virus (HBV), hepatitis C virus (HCV) or both
and thus at risk for cirrhosis and hepatocellular carcinoma. HBV
and HCV pose a particularly vexing clinical problem in organ
transplant recipients [1]. HBV- or HCV-associated end stage liver
disease is the leading indication for orthotopic liver transplantation
(OLT). In the case of HCV re-infection of the graft is near
universal. Recurrent hepatitis C rapidly progresses to cirrhosis and
thus frequently necessitates re-transplantation [2]. Of the hemo-
dialysis population 0–10% and 10–65% are infected with HBV or
HCV, respectively [3].
Immunosuppression itself results in enhanced viral replication, but
as shown by us and others some immunosuppressive agents have
additional direct non-immune mediated effects on viral replication:
while cyclosporine A (CsA) and its derivatives are potent inhibitors of
HCV-replication and are now being developed as anti-viral drugs [4],
glucocorticoids have been found to directly stimulate a glucocorticoid-
responsive element present in the HBV genome [5] and to enhance
HCV-infection of liver cells [6]. To design optimal immunosuppres-
sive regimens in transplant recipients with viral hepatitis it is important
to be aware of these properties.
Sotrastaurin (AEB071) is a novel immunosuppressive drug
currently in phase I and II clinical trials for post transplant
immunosuppression [7] and may also provide a new therapeutic
option for psoriasis [8]. It inhibits multiple classical and novel
members of the protein kinase C (PKC) family resulting in
decreased T-lymphocyte activation [9]. However PKC-family
members have a plethora of additional effects on non-immune
cells including hepatocytes. The replication of HBV, a DNA virus
of the Hepadnaviridae family, and HCV, a plus-strand RNA-virus of
the Flaviviridae family, is intricately linked to PKC-dependent
cellular processes [10,11,12]. Yet, whether sotrastaurin has a direct
effect on HBV- and/or HCV-replication has not been addressed
experimentally.
Using cell based in vitro infection systems capable of recapitu-
lating the entire replication cycle of these viruses we observed no
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concentration tested. These data indicate that sotrastaurin may be
a viable option to achieve immunosuppression in HBV and/or
HCV infected solid organ transplant recipients.
Materials and Methods
Drugs
Sotrastaurin (AEB071) and cyclosporin A were provided by
Novartis, Basel, Switzerland. Tacrolimus and Bisindolylmaleimide
I (BIM-I) were purchased from Sigma-Aldrich (Seelze, Germany).
All were dissolved in dimethyl sulfoxide (DMSO).
Plasmids
The subgenomic JFH1 NS3-5B HCV reporter genome (SG-
JFH1-Luc) that encodes firefly luciferase as a sensitive marker of
viral genome replication and the full length HCV reporter genome
Jc1-Luc also encoding firefly luciferase and a chimeric JFH1
(genotype 2a; GenBank accession no AB047639) and J6/CF
(genotype 2a; GenBank accession no AF177036) HCV genome
have been described recently [4,6,13]. The H77/JFH1 chimeric
HCV genome was a kind gift from Jens Bukh (Copenhagen
University Hospital, Copenhagen, Denmark) [14].
Cell Culture
Huh-7.5 [15] and HepaRG [16] cells were cultured as
previously described [4,17]. Four weeks before infection, HepaRG
cells were seeded into 12-well plates (Corning, Kaiserslautern,
Germany) at 1,25610
5 cells per well. Two weeks prior to infection
differentiation was induced by adding 0.5% DMSO [17].
Cell culture grown HCV particle (HCVcc) assays
Assays for HCV genome replication, production of newly
formed HCVcc and infection of naive cells were performed using
HCV strains Jc1-Luc (containing a luciferase reporter) or chimeric
H77/JFH1 genomes and highly HCV-susceptible Huh-7.5 human
hepatoma cells as previously described [4,6]. All luciferase assays
were performed in duplicate (replication) or quadruplicates
(infection). To measure HCV spread between adjacent cells (cell-
to-cell route) we performed a modified version of a recently
described agarose overlay assay [18] where ‘‘donor’’ Huh-7.5 cells
were infected with HCVcc (H77/JFH1 chimera) at a high
multiplicity of infection resulting in .99% HCV-positive cells as
assessed by NS5A staining. ‘‘Target’’ Huh-7.5 cells were
transduced with a pTRIP-tagRFP-NLS-IPS1 reporter construct
recently described by Jones and colleagues consisting of a fusion
protein of the red fluorescent protein tagRFP, an SV40 nuclear
localization sequence (NLS) and the C-terminal part (amino acids
462–540) of the interferon-b promoter stimulator protein 1 (IPS1)
[19]. The C-terminus of IPS-1 contains an NS3/4A protease
cleavage site upstream of a mitochondrial membrane anchor.
HCV infection then results in relocation of the tagRFP reporter
from a punctuate cytosolic pattern of fluorescence (uninfected) to
the nucleus (infected). HCV-positive donor and HCV-negative
target cells were mixed at a 1:1 ratio and seeded at 4610
4 cells per
well into 12-well plates. The co-culture was overlaid with 1%
Seaplaque low melting temperature agarose to prevent virus
spread through the cell-free route. After 96 hours agarose was
removed, the cells were co-stained with DAPI and the percentage
of infected target cells was determined.
Lentiviral HCV pseudo-particle (HCVpp) assays
Pseudoparticles were generated as previously described in 293T
cells by co-transfection of (1) a lentigenome with a GFP reporter;
(2) HIV gag-pol and (3) the HCV glycoproteins E1 and E2 of
strain H77 or JFH-1 with Fugene (Roche Diagnostics, Mannheim,
Germany) [20]. For pseudovirus transduction filtered supernatants
were added to the target cells for 6 hours. Reporter expression was
measured after 48 hours.
Cell viability and proliferation assay
To probe for cytotoxic effects, Huh-7.5 cells were stained with a
LIVE/DEAD fixable far red dead cell stain kit from Invitrogen
(Darmstadt, Germany) according to the manufactures protocol.
The cells were washed twice and immediately analysed on a
fluorescence-activated cell sorter (FACSCanto II, Becton-Dick-
inson, Heidelberg, Germany). Data were analysed using FloJo
software (Tree Star, Inc. Oregon Corporation, Ashland, OR).
Alternatively, the Cytotoxicity Detection Kit PLUS that measures
lactate dehydrogenase (LDH) release from damaged cells was used
(Roche Diagnostics, Mannheim, Germany). To measure the
percentage of proliferating cells we used the BrdU Labeling kit I
(Roche Diagnostics, Mannheim, Germany) according to the
manufacturer’’s instructions. Cell viability and proliferation assay
were done at the same time as the corresponding replication or
infectivity measurements unless stated otherwise.
HBV assays
HBV virions were generated in HepAD38 cells that contain a
Tet-regulated HBV genome [21]. Briefly, supernatant from
induced (Tet off) AD38 cells was purified by low speed
centrifugation, precipitated overnight at 4uC with 6% polyethyl-
ene glycol 8000 (PEG 8000; Sigma), concentrated by centrifuga-
tion (8000 6g, 60 min, 4uC), resuspended in 1/100 of the initial
volume of PBS with 12.5% FCS, and frozen in aliquots at 280uC.
For infection, differentiated HepaRG cells (see cell culture section
above) were inoculated with 500 ml of medium containing 4%
PEG 8000, 2% DMSO and 25 ml of the concentrated virus stock.
After overnight incubation the cells were washed three times with
PBS and further cultivated for at least nine days. HBsAg and
HBeAg in the culture supernatant were determined at day 9 by
using Abbott AxSYM assays for HBeAg and HBsAg (Abbott,
Wiesbaden, Germany).
Results
Effect of sotrastaurin on HCV RNA replication and
infectivity
Huh-7.5 cells were electroporated with the in vitro transcribed
HCV Jc1-Luc genome and 4 hours later increasing amounts of
sotrastaurin were added to the medium. Replication efficiency was
assessed 4, 24, 48 and 72 hours after transfection (Fig. 1A). There
was no sotrastaurin-induced enhancement of HCV replication
detectable. High doses of sotrastaurin (10 mg/ml) decreased HCV
RNA replication in transfected cells about 8-fold at 48 hours. At
72 hours replication had reached a plateau for all tested
concentrations of sotrastaurin. At this time point RNA levels in
cells exposed to 10 mg/ml sotrastaurin reached levels below but
close to those measured in untreated cells. In parallel the culture
fluid collected 72 hours after transfection was used to inoculate
naı ¨ve Huh-7.5 cells to probe for an effect on virus production
(Fig. 1B). Luciferase activity in the inoculated cells was reduced up
to 10-fold. When sotrastaurin was applied to Huh-7.5 cells
harboring an NS3-5B subgenomic replicon with a luciferase
reporter (SG-JFH1-Luc), again a dose dependent reduction of
HCV RNA replication was detected (Fig. 1C). Moreover, the PKC
inhibitor BIM-I that has previously been reported to inhibit HCV
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24142Figure 1: Differential effect of sotrastaurin on HCV RNA replication and virus infection. (A) Replication of HCV in the presence of
sotrastaurin at 4, 24, 48 and 72 h post transfection. (B) Inoculation of naı ¨ve Huh-7.5 cells using culture fluid from the cells shown in Fig. 1A. After 4 h,
cells were supplemented with fresh medium without sotrastaurin. (C+D) Treatment of Huh-7.5 cells harboring a subgenomic HCV replicon (SG-JFH1-
Luc) with increasing concentrations of (C) sotrastaurin or (D) BIM-I. The DMSO control corresponds to the DMSO concentration present with the
highest drug concentration tested. The luciferase assay was performed 48 hours post transfection. (E) Huh-7.5 cells were treated with increasing
amounts of sotrastaurin. After 48 h cell were stained with a live/dead cell stain kit and analyzed by FACS. (F) Percentage of BrdU-positive cells after
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SG-JFH1-Luc in our hands (Fig. 1D).
Given that the sotrastaurin concentrations used in the above
experiments are well above the levels achieved in clinical use of the
drug, the observed reduction in HCV replication could be due
direct anti-viral activity or indirectly mediated through non-
specific cytotoxic and/or anti-proliferative effects of the drug. In a
standard cytotoxicity assay using a dead cell marker there was no
detectable cytotoxicity when cells were exposed to a concentration
of 50 mg/ml for 72 hours (Fig. 1E). At 100 and 500 mg/ml about
50% and 100% non-viable cells were detected, respectively. Since
sotrastaurin is known to be a potent inhibitor of cell proliferation,
we also performed a standard BrdU assay and observed growth
arrest in a percentage of cells beginning at concentrations of
48 hours. (G) Luciferase activity as an aggregate measure of viability and proliferation in Huh-7.5 cells stably expressing luciferase under a CMV-
promoter treated with sotrastaurin for 72 h.
doi:10.1371/journal.pone.0024142.g001
Figure 2: Effect on early HCV replication cycle stages. (A) Infection of Huh-7.5 cells with Jc1-Luc produced in the absence of sotrastaurin. The
drug was added for at least 4 h during infection. (B) Strain H77 HCVpp infection of Huh-7.5 cells in the presence or absence of sotrastaurin.
Pseudoparticles bearing the glycoprotein of the vesicular stomatitis virus (VSVG) served as controls. (C) Pseudoparticle infection of Huh-7.5 cells in the
presence of increasing concentrations of BIM-I. pcDNA represents pseudoparticles devoid of viral glycoproteins.
doi:10.1371/journal.pone.0024142.g002
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measure of cell proliferation and viability we used VSV-G
pseudoparticles to create a population of Huh-7.5 cells stably
expressing firefly luciferase from a CMV-promoter. We treated
these cells with different concentrations of sotrastaurin for
72 hours. In line with the above standard assays, a reduction in
luciferase activity was detectable at concentrations of 30 mg/ml
sotrastaurin and above (Fig. 1G). Taken together, in the Huh-7.5
cells used in our assays sotrastaurin displays anti-proliferative
effects at concentrations where a reduction in HCV replication
becomes detectable. This suggests that the observed effects on
HCV are indirectly mediated through alterations in cellular
growth and/or viability rather than being a reflection of a direct
anti-viral activity of sotrastaurin.
Sotrastaurin does not affect HCV entry
When using Jc1-Luc viruses prepared in the absence of
sotrastaurin to infect naı ¨ve Huh-7.5 cells and adding the drug
only during inoculation we observed a 3-fold reduction of
infectivity (Fig. 2A). Again, this parallels the anti-proliferative
effects of high sotrastaurin concentrations described above (Fig. 1F)
and is thus not indicative of a specific anti-viral activity. To
formally rule out an effect of sotrastaurin on HCV entry, we next
used HCV pseudoparticles (HCVpp). HCVpp only test the entry
step in the HCV replication cycle without any interference from
effects on HCV replication. Here we did not observe an inhibitory
effect of sotrastaurin on HCVpp bearing the HCV-glycoproteins
E1E2 of genotype 1 or 2 (Fig. 2B and data not shown). Thus even
high concentrations of sotrastaurin do not impact on HCV cell
entry. The PKC-inhibitor BIM-I, previously described to inhibit
HCV RNA replication [12], also had no HCV-specific effect on
cell entry (Fig. 2C).
Sotrastaurin does not affect cell-to-cell transmission of
HCV
Besides de novo infection of cells by viral particles in the blood
stream HCV is thought to spread within the liver tissue directly to
cells adjacent to infected hepatocytes. This cell-to-cell route is
thought to circumvent the ‘‘extracellular virion’’ stage of the
replication cycle and accordingly be resistant to neutralizing
antibodies present in the extracellular space. To test if sotrastaurin
has an effect on this route of viral spread we used a co-culture
assay (cf. methods section and figure legend) and observed an
equal percentage of infected target cells in the presence or absence
of 10 mg/ml sotrastaurin (Fig. 3A+B) indicating that cell-to-cell
spread is not inhibited.
Sotrastaurin does not alter the inhibitory effects of CsA
on HCV
Transplant recipients are usually treated with a combination of
two or more immunosuppressive drugs. Among potential combi-
nation partners of sotrastaurin, CsA is known to have a strong
inhibitory effect on HCV RNA replication. To rule out that the
combination of CsA with sotrastaurin might influence the antiviral
effect of CsA and in order to mimic real-life conditions we tested
combinations of sotrastaurin with CsA or tacrolimus, a calcineurin
inhibitor with no direct effect on HCV replication. As shown in
Figure 3: Sotrastaurin does not affect cell-to-cell spread of HCV. (A) HCV-positive donor cells were mixed with HCV-negative target cells
under an agarose overlay preventing cell-free virus spread in the presence or absence of sotrastaurin. Target cells contained a tagRFP-reporter that
assumes a cytosolic or nuclear localization depending whether the cells are uninfected or infected with HCV. After 96 hours of co-culture nuclei were
co-stained with DAPI. (B) Percentage of infected target cells after 96 hours of co-culture.
doi:10.1371/journal.pone.0024142.g003
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the presence or absence of sotrastaurin. As expected, tacrolimus
had no effect on HCV RNA replication (Fig. 4B). In the presence
of either CsA or tacrolimus, there was a reduction in HCV
replication when 10 mg/ml or more of sotrastaurin was present
which again is likely due to anti-proliferative and/or cytotoxic
effects of high drug concentrations.
Effects of sotrastaurin on the HBV lifecycle
To address the question if the novel PKC inhibitor sotrastaurin
has an influence on HBV we infected differentiated HepaRGs in
the presence or absence of sotrastaurin. HBeAg and HBsAg in the
supernatant were measured by ELISA 9 days after inoculation
(Fig. 5A and data not shown). To distinguish HBV antigen
synthesized in de novo infected cells from antigens in the
inoculums, we performed a control experiments where infection
was blocked with HBVpre-S/2-48
myr, a peptide that efficiently
blocks HBV entry [17]. As shown in Figure 5A, there was a small
(about 3-fold) reduction supernatant antigen levels when sotras-
taurin (5 or 10 mg/ml) was present during the entire experiment.
In contrast, the presence of sotrastaurin only during the initial
16 hours had no effect, suggesting that HBV entry is not affected
by the drug. When sotrastaurin was added after the initial 16 hour
inoculation period there was a modest reduction of the infection
signal. An enhancement of HBV infection was not observed in any
case. In a cytotoxicity assay measuring LDH release no cytotoxic
Figure 4: Combination of sotrastaurin with calcineurin inhibitors. (A, B) Effect of different concentrations of sotrastaurin plus (A) CsA or (B)
tacrolimus on HCV Jc1-Luc replication at 48 h after electroporation.
doi:10.1371/journal.pone.0024142.g004
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24142Figure 5: Effects of sotrastaurin on the HBV lifecycle. (A) Differentiated HepaRG cells were infected with HBV virions. Sotrastaurin 5 or 10 mg/
ml was present either during inoculation (initial 16 h), during inoculation and infection (throughout), or after inoculation (from 16 h onwards). An
inhibitory fragment from the HBV L-protein (HBV pre-S/2-48my) applied during inoculation served as a positive control. All reactions were adjusted to
contain the same final concentration of DMSO. HBeAg levels secreted into the cell culture supernatant were determined at day 9 after infection. (B)
Cytotoxic effect of sotrastaurin on differentiated HepaRG cells as measured by and LDH release assay. (C) HBV antigens released from AD38 harboring
a replicating HBV genome after 72 hours of sotrastaurin treatment. IU – international units; S/CO - signal to cutoff ratio. (D) AD38 cells were treated
with increasing amounts of sotrastaurin. After 72 h cells were stained with a live/dead cell stain kit and analyzed by FACS.
doi:10.1371/journal.pone.0024142.g005
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ml (Fig, 5B). In AD38 cells harboring a replicating HBV genome
there was only a minimal effect on HBeAg release detectable while
HBsAg release was completely unaffected by sotrastaurin concen-
trations up to 50 mg/ml (Fig. 5C). In a standard cytotoxicity assay
using a dead cell marker there was an increase in the percentage of
non-viable cells beginning at 50 mg/ml sotrastaurin exposure for
72 hours. (Fig. 5D).
Discussion
The pan-PKC inhibitor sotrastaurin (AEB071) is a novel
immunosuppressive drug. Currently phase II trials evaluate the
combination of sotrastaurin and other immunosuppressive drugs
in the post solid organ transplant setting (liver and kidney). Patients
with viral hepatitis as yet are excluded from these trials.
To our knowledge this is the first experimental study testing for
non-immune mediated effects of sotrastaurin on HBV or HCV
replication. The most important finding of this study is that
sotrastaurin does not upregulate HBV or HCV replication in any
of our assay. These results support that sotrastaurin may be a
viable option for immunosuppression in HBV and/or HCV
infected organ transplant recipients.
We found that sotrastaurin reduces HCV replication at levels of
10 mg/ml and above which is equivalent to the concentrations
where anti-proliferative effects become detectable (10 mg/ml).
Overt cytotoxicity was seen at only slightly higher concentration
(50-100 mg/ml). Hence we believe that sotrastaurin has no specific
activity against HCV, but rather affects the intracellular milieu in
a way that indirectly reduces viral replication. It is even
conceivable that the presence of the replicating viral genome
makes cells more vulnerable to pharmacologically induced
apoptosis as has been shown for HCV and actinomycin D and
staurosporine [22]. Although we did not evaluate the rate of
apoptosis, similar mechanisms, i.e. HCV aggravating anti-
proliferative or pro-apoptotic effects of sotrastaurin, could be at
play here. Clearly, the sotrastaurin concentrations needed to
achieve any reduction in viral replication are much higher than
those clinically achieved in humans where the pre-dosing levels of
sotrastaurin in kidney transplant recipients are reported in the
range of 0.2–1 mg/ml [23]. Thus a virologic, non-immune
mediated effect of sotrastaurin on HCV replication in correctly
dosed patients is unlikely and – if existent – of no clinical
relevance. Murakami and colleagues have reported a mild
inhibitory effect on HCV by the PKC-inhibitor BIM-I [12] which
we have also observed. BIM-I primarily targets classical PKC
isoforms and, to our knowledge, is not under investigation for any
clinical application. What part of the HCV replication cycle is
affected by BIM-I has not been reported, but our data suggest that
RNA replication rather than cell entry is reduced. This apparent
difference between the PKC-inhibitors BIM-I and sotrastaurin
could well be due to a distinct profile of activity against different
PKC isoforms.
In the case of HBV 5 or 10 mg/ml sotrastaurin reduced
intracellular genome replication while cytotoxic effects became
apparent at 25 mg/ml. Presence of the drug only during cell entry
had no effect and its administration only after cell entry has been
completed (16 hours) had a very small effect. Given this as well as
the negligible effect on HBV in AD38 cells where replication is
already well established before the drug is administered, one could
speculate that it is the initiation of viral replication that is most
sensitive to sotrastaurin. The HBV assays employed do not permit
sensitive detection of effects on new particle production since new
particle assembly in differentiated HepaRG cells is thought to be
very low. The effect of sotrastaurin on HBV appears small and its
mechanism is unclear. Although there was no cytotoxicity
detectable at the concentrations where the reduction in HBV
replication was seen cytotoxicity became apparent at only slightly
higher concentrations and it is certainly possible that non-specific
perturbations of the intracellular milieu at slightly sub-toxic
concentrations adversely affect viral replication. However, the
viral transcriptional activators HBx and PreS2-activator large
surface protein have both been reported to trigger signaling
processes involving PKC so that an anti-viral effect of PKC-
inhibition by sotrastaurin would also be plausible [10,24,25].
Based on our data we can rule out a direct pro-viral effect of
sotrastaurin on either HBV or HCV at any concentration tested.
This is important information when considering the use of this
immunosuppressant in HBV- and/or HCV-positive recipients of
solid organ transplants. Differently from what has been reported
for the PKC inhibitor BIM-I we have no evidence for any anti-
HCV effect of sotrastaurin even at drug concentrations well above
what is clinically achieved in transplant recipients taking
sotrastaurin for immunosuppression. Based on our data a small
inhibitory effect of sotrastaurin on HBV replication is possible
albeit only at concentrations well above what is clinically achieved.
Thus based on our findings we do not expect any clinically
significant non-immune mediated pro- or anti-viral effect of
sotrastaurin on either HBV or HCV.
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